

Editorial

Delayed Onset Post-ERCP Pancreatitis (DOPE-P)

Vishal Khurana, MBBS, MD, DM, MNAMS*

Department of Gastroenterology, Metro Heart Institute with Multispeciality, Faridabad, Haryana, India

*Corresponding author

Vishal Khurana, MBBS, MD, DM, MNAMS

Consultant, Department of Gastroenterology, Metro Heart Institute with Multispeciality, Faridabad, Haryana, India; E-mail: vishdoc24@gmail.com

Article information

Received: May 7th, 2018; Accepted: August 2nd, 2018; Published: August 8th, 2018

Cite this article

Khurana V. Delayed onset post-ERCP pancreatitis (DOPE-P). *Pancreas Open J.* 2018; 2(1): e8-e9. doi: [10.17140/POJ-2-e008](https://doi.org/10.17140/POJ-2-e008)

Post Endoscopic retrograde cholangiopancreatography (ERCP) Pancreatitis (PEP) is defined as new onset or worsening of pain abdomen after ERCP with an elevation of pancreatic enzymes (amylase/lipase) more than 3 times upper limit of normal after 24 hours of procedure and prolongation of hospital stay/planned admission.^{1,2,3} The overall incidence of PEP is estimated to be 3-10%.^{1,2,3} Various risk factors found in multivariate trials are divided into patient-related risk factor (prior PEP, female sex, young patient, normal bilirubin, previous recurrent pancreatitis, suspected sphincter of Oddi dysfunction, absence of chronic pancreatitis) and procedure-related risk factors (difficult cannulation i.e. >10 minutes cannulation time, repetitive pancreatic duct guide wire cannulation, pancreatic duct contrast injection, pancreatic sphincterotomy, endoscopic papillary large-balloon dilatation of an intact sphincter). Placement of prophylactic pancreatic stents (PPSs) usually advocated in high-risk patients and reduced PEP rate by 60-80%.^{4,5} 3 Fr stents have higher migration rate and hence 5 Fr stents are superior to 3 Fr. Studies have shown that if placement of pancreatic stent is attempted but fails risk of PEP increases.⁶

There is scarce data available on incidence and severity of delayed onset post ERCP pancreatitis (DOPE-P).^{7,8} DOPE-P is defined as the development of features of pancreatitis after the first 24 hrs of ERCP. It can occur in two situations: either early migration of prophylactic pancreatic duct (PD) stent within first day of ERCP or after endoscopic removal of PD stent. A retrospective cohort study of 230 patient undergoing PPS removal has shown 3% incidence of pancreatitis after pancreatic stent removal. Statistical significant risk factors found in this study were use of 5 fr a stent, stent with internal flange and history of PEP after initial ERCP.⁸ Probable etiology of DOPE-P is trauma to PD caused by stent removal. There is a need for a prospective trial for incidence, severity and prevention of DOPE-P. Judicious use of PPS in the only high-risk ERCP with slow removal of PPS within

5-10 days or pharmacoprophylaxis with rectal Nonsteroidal anti-inflammatory drug (NSAIDs), if stent removal done after 10 days, it may theoretically decrease the incidence of DOPE-P. Guidelines recommends evaluation of self-migration of PPS within 5-10 days of placement and endoscopic removal if stent do not migrate with 5-10 days.¹

CONFLICTS OF INTEREST

None.

REFERENCES

1. Dumonceau JM, Andriulli A, Elmunzer BJ, et al. Prophylaxis of post-ERCP pancreatitis: European society of gastrointestinal endoscopy (esge) guideline - updated june 2014. *Endoscopy.* 2014; 46(9): 799-815. doi: [10.1055/s-0034-1377875](https://doi.org/10.1055/s-0034-1377875)
2. ASGE Standards of Practice Committee, Anderson MA, Fisher L, Jain R, et al. Complications of ERCP. *Gastrointest Endosc.* 2012; 75(3): 467-73. doi: [10.1016/j.gie.2011.07.010](https://doi.org/10.1016/j.gie.2011.07.010)
3. ASGE Standards of Practice Committee, Chandrasekhara V, Khashab MA, Muthusamy VR, et al. Adverse events associated with ERCP. *Gastrointest Endosc.* 2017; 85(1): 32-47. doi: [10.1016/j.gie.2016.06.051](https://doi.org/10.1016/j.gie.2016.06.051)
4. Mazaki T, Masuda H, Takayama T. Prophylactic pancreatic stent placement and post-ERCP pancreatitis: A systematic review and meta-analysis. *Endoscopy.* 2010; 42: 842-853. doi: [10.1055/s-0030-1255781](https://doi.org/10.1055/s-0030-1255781)
5. Choudhary A, Bechtold ML, Arif M, et al. Pancreatic stents-for prophylaxis against post-ERCP pancreatitis: A meta-analysis and systematic review. *Gastrointest Endosc.* 2011; 73: 275-282. doi:

[10.1016/j.gie.2010.10.039](https://doi.org/10.1016/j.gie.2010.10.039)

6. Choksi NS, Fogel EL, Cote GA, et al. The risk of post-ERCP pancreatitis and the protective effect of rectal indomethacin in cases of attempted but unsuccessful prophylactic pancreatic stent placement. *Gastrointest Endosc.* 2015; 81(1): 150-155. doi: [10.1016/j.gie.2014.07.033](https://doi.org/10.1016/j.gie.2014.07.033)

7. Freeman ML. Use of Prophylactic Pancreatic Stents for the Prevention of Post-ERCP Pancreatitis. *Gastroenterol Hepatol (N Y)*. 2015; 11(6): 420-422.

8. Moffatt DC, Coté GA, Fogel EL, et al. Acute pancreatitis after removal of retained prophylactic pancreatic stents. *Gastrointest Endosc.* 2011; 73(5): 980-986. doi: [10.1016/j.gie.2011.01.012](https://doi.org/10.1016/j.gie.2011.01.012)